683 Capital Management LLC Invests $539,000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

683 Capital Management LLC bought a new stake in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 217,265 shares of the biotechnology company's stock, valued at approximately $539,000. 683 Capital Management LLC owned 0.30% of Aclaris Therapeutics at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Geode Capital Management LLC grew its holdings in Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company's stock worth $974,000 after acquiring an additional 72,309 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Aclaris Therapeutics by 113.9% in the fourth quarter. Assenagon Asset Management S.A. now owns 397,362 shares of the biotechnology company's stock worth $985,000 after purchasing an additional 211,585 shares during the last quarter. Peapod Lane Capital LLC bought a new position in Aclaris Therapeutics during the 4th quarter valued at approximately $1,003,000. Charles Schwab Investment Management Inc. bought a new stake in shares of Aclaris Therapeutics in the 4th quarter worth approximately $82,000. Finally, Raymond James Financial Inc. purchased a new stake in Aclaris Therapeutics in the fourth quarter worth $383,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Trading Down 1.2 %

NASDAQ:ACRS traded down $0.02 on Wednesday, reaching $1.27. 244,476 shares of the stock traded hands, compared to its average volume of 1,180,896. The company's fifty day simple moving average is $1.45 and its 200 day simple moving average is $2.24. The company has a market capitalization of $136.98 million, a price-to-earnings ratio of -2.43 and a beta of 0.42. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on ACRS shares. StockNews.com lowered shares of Aclaris Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, February 8th. Scotiabank started coverage on Aclaris Therapeutics in a research report on Friday, March 7th. They set a "sector outperform" rating and a $15.00 price target on the stock. Finally, Cantor Fitzgerald began coverage on shares of Aclaris Therapeutics in a report on Tuesday, March 18th. They set an "overweight" rating on the stock. One investment analyst has rated the stock with a sell rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Aclaris Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $11.67.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.